european end-to-end CDMO company, pharma services
  • About us
    • History
    • Leaderships
    • Team
    • EU grants
    • Requests for Proposal
    • Sustainability – ESG
    • Bussines strategy
    • Quality policy
    • Virtual Tour
  • Services
    • Drug Substance Manufacturing
    • Fill & Finish
    • Gene to Vial: End-to-End Development
    • Process Development
    • Analytics 
    • Cell Line Development & Banking
  • Science Hub
    • Science News
    • Resources
  • News & Events
    • Press releases
    • Events
    • Content to download
  • Investors
    • Corporate documents
    • Shareholders and shares
    • Periodic reports
    • Current reports
    • Sustainability reports
    • Corporate governance at Mabion
    • Financial data
    • For Investors
    • Calendar
  • Contact us
    • Contact form
    • Contact for investors
    • Contact for media
    • Careers
  • EN
  • Science News
  • Resources

Biologics

gmp biologics manufacturing

GMP Biologics Manufacturing in End-to-End Drug Development

Biologics, Drug development, GMP, Manufacturing
Biggest Analytical Challenges in Biosimilar Characterization and Comparability

5 Analytical Challenges in Biosimilar Characterization and Comparability

Biologics, Drug development
Integrated modeling of upstream and downstream bioprocessing to improve biologics production efficiency

Poster

Integrated Modeling of Upstream and Downstream Bioprocessing to Improve Biologics Production Efficiency

Biologics, Drug development, Mabion, Manufacturing
What Can Video Games Teach Us About Contract Biopharma cover photo

What Can Video Games Teach Us About Contract Biopharma?

Biologics
automatic assay HTS

The Role of High-Throughput Screening (HTS) in Cell Line Development and Process Optimization

Biologics, Drug development
quality control of biologics

Quality Control of Biologics Ensuring Safety Through Aggregation Analysis

Analytics, Biologics, GMP, Proteins
Co-Development Partnership Models in Biologics Programs

Co-Development Partnership Models in Biologics Programs

Biologics, Drug development, Mabion, Partnership
innovative biologics 2026

Innovative Biologics Expected Approvals in 2026

Antibody-drug conjugates, Biologics, Bispecific antibody, Clinical trials, EMA, FDA, Monoclonal antibody, Vaccines
Declaration of the objectives and scope of the European Biotech Act

EU Biotech Act Ignites a New Wave of Biologics Partnerships

Biologics, Clinical trials, EMA, Regulatory
1 2 3 Next

Contact

Find out how we may support your business.

bd@mabion.eu

Mabion

gen. Mariana Langiewicza 60
95-050 Konstantynów Łódzki
Poland

+48 42 207 78 90

    Mabion
    • Privacy policy
    • Services
    • Investors
    • News&Events
    • Contact us

    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

    Powered by

    Veneo